DTIC-Dome 500mg Injection

DTIC-Dome 500mg Injection belongs to the category of anticancer medicines. It is used in the treatment of skin cancer that has spread to other body parts, and Hodgkin's disease (cancer that affects the lymphatic system). The active ingredient of the DTIC-Dome is Dacarbazine, which belongs to the drug class of alkylating agents.

It is administered as an injection by an experienced nurse or medical professional. DTIC-Dome Injection works by killing the cancer cells, thereby reducing the size of the tumor. In this way, it prevents cancer cells from spreading to other parts of the body. The doctor decides the required dosage and duration of the medicine.

The human body shows undesired symptoms after taking DTIC-Dome 500mg Injection. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Some of the common side effects of DTIC-Dome Injection are mentioned below:

• Nausea
• Vomiting
• Hair loss
• Headache
• Skin reactions
• Loss of appetite
• Vision problems
• Low levels of RBC, WBC, and platelets

Serious side effects are:

• Sore throat
• Liver problems
• Allergic reaction
• Extreme tiredness
• Numbness in the face
• Fits, confusion, & lethargy
• Severe vomiting or diarrhea
• Unusual bleeding or bruising
• High temperature indicating infection

Swelling in different body parts (hands, feet, ankles, face, lips, mouth or throat

• DTIC-Dome 500mg Injection is a prescription-based anticancer drug. It is advised to take this injection after consulting your healthcare expert.
• This medicine should be given intravenously by an experienced nurse or doctor. Please do not self-administer.
  
  

• The active ingredient of the DTIC-Dome is Dacarbazine, which belongs to the drug class of alkylating agents that works by alkylation. It inhibits DNA synthesis, which disturbs the normal functioning of DNA.
• This process arrests the growth and proliferation of cancer cells, eventually leading to their death. In this way, it slows the progression of cancer.
  

It is advised not to miss any scheduled dosage of DTIC-Dome 500mg Injection. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

It is advised to use effective birth control methods and avoid pregnancy during the treatment with DTIC-Dome 500mg Injection.

A person should avoid smoking while undergoing treatment with DTIC-Dome 500mg Injection. Smoking may reduce the effectiveness of medicine.

Monitor your blood sugar & pressure, Kidney & Liver function (KFT & LFT), Heart function at proper intervals after taking DTIC-Dome 500mg Injection.

Swelling of hands, lips, and weight gain are some of the side effects observed after taking DTIC-Dome 500mg Injection. To reduce them, the doctor may suggest some medication.

Skin becomes extremely sensitive after taking DTIC-Dome 500mg Injection. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.

It is advised to avoid taking analgesics/ antacids (medicines used to neutralize the stomach acid) while taking DTIC-Dome 500mg Injection, as it may reduce the effectiveness of the medicine.

Keep your body hydrated as Diarrhea is one of the common side effects experienced after taking DTIC-Dome 500mg Injection. Consult your doctor if it doesn't stop or if blood appears in your stools.

• Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., ... & Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517-2526. https://www.nejm.org/doi/full/10.1056/NEJMoa1104621
• Ugurel, S., Paschen, A., & Becker, J. C. (2013). Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent. Journal of Investigative Dermatology, 133(2), 289-292. https://pubmed.ncbi.nlm.nih.gov/23318786/
• Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaletti, R., Boni, C., ... & Bacchi, M. (1992). Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England Journal of Medicine, 327(8), 516-523. https://pubmed.ncbi.nlm.nih.gov/1635566/
• Eggermont, A. M., & Kirkwood, J. M. (2004). Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. European journal of cancer, 40(12), 1825-1836. https://pubmed.ncbi.nlm.nih.gov/15288283/
• Al-Badr, A. A., & Alodhaib, M. M. (2016). Dacarbazine. Profiles of Drug Substances, Excipients and Related Methodology, 41, 323-377. https://www.researchgate.net/publication/297713633_Dacarbazine